Arcus Biosciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Arcus Biosciences Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Hayward
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RCUS
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001724521
- EIN
- 47-3898435
Board of directors
-
Andrew J. Perlman · DirectorSince 2023
-
Antoni Ribas · DirectorSince 2023
-
David L. Lacey · DirectorSince 2023
-
Dietmar Berger · DirectorSince 2025
- Since 2023
-
Johanna Mercier · DirectorSince 2024
-
Juan C. Jaen · Director · PresidentSince 2023
-
Kathryn E. Falberg · DirectorSince 2023
-
Nicole Lambert · DirectorSince 2023
-
Patrick Machado · DirectorSince 2023
-
Terry J. Rosen · Director · Chief Executive OfficerSince 2023
-
Yasunori Kaneko · DirectorSince 2023
Chief executives
Terry J. Rosen
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.4%
-
82.4%
-
82.4%
-
88.8%
Board connections
6 of this board's directors also sit on 11 other boards.
- via Patrick Machado
- via Jennifer Jarrett
- via Terry J. Rosen
- via Johanna Mercier
- via David L. Lacey
- via Kathryn E. Falberg
- via Jennifer Jarrett
- via Jennifer Jarrett
- via Kathryn E. Falberg
- via Patrick Machado
- via Jennifer Jarrett
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $14,411,829
- 45 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 21, 2026 | Azoy Alexander Officer (Chief Accounting Officer) | Option exercise | +2,827 | $15.44 | $43,649 |
| Aug 21, 2026 | Azoy Alexander Officer (Chief Accounting Officer) | Open-market sale | −2,827 | $30.00 | $84,810 |
| Jul 10, 2026 | Juan C. Jaen Officer (President) | Open-market sale | −19,799 | $28.61 | $566,410 |
| Jul 10, 2026 | Juan C. Jaen Officer (President) | Open-market sale | −268 | $29.40 | $7,878 |
| Jul 9, 2026 | Juan C. Jaen Officer (President) | Open-market sale | −48,502 | $30.05 | $1,457,631 |
| Jun 24, 2026 | Juan C. Jaen Officer (President) | Open-market sale | −6,431 | $29.66 | $190,743 |
| Jun 23, 2026 | Juan C. Jaen Officer (President) | Open-market sale | −14,067 | $27.69 | $389,515 |
| Jun 23, 2026 | Juan C. Jaen Officer (President) | Open-market sale | −1,697 | $28.06 | $47,618 |
| Jun 22, 2026 | Juan C. Jaen Officer (President) | Open-market sale | −9,236 | $27.03 | $249,649 |
| Jun 11, 2026 | Nicole Lambert Director | Grant or award | +5,700 | — | — |
| Jun 11, 2026 | Patrick Machado Director | Grant or award | +5,700 | — | — |
| Jun 11, 2026 | Yasunori Kaneko Director | Grant or award | +5,700 | — | — |
| Jun 11, 2026 | Tang Carolyn C. Officer (General Counsel) | Option exercise | +34,090 | $2.57 | $87,611 |
| Jun 11, 2026 | David L. Lacey Director | Grant or award | +5,700 | — | — |
| Jun 11, 2026 | Kathryn E. Falberg Director | Grant or award | +5,700 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.